These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 18793346

  • 1. Common exon 3 polymorphism of the GH receptor (GHR) gene and effect of GH therapy on growth in Korean children with idiopathic short stature (ISS).
    Ko JM, Park JY, Yoo HW.
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):82-7. PubMed ID: 18793346
    [Abstract] [Full Text] [Related]

  • 2. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.
    Ko JM, Kim JM, Cheon CK, Kim DH, Lee DY, Cheong WY, Kim EY, Park MJ, Yoo HW.
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916
    [Abstract] [Full Text] [Related]

  • 3. Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children.
    Ballerini MG, Domené HM, Scaglia P, Martínez A, Keselman A, Jasper HG, Ropelato MG.
    Growth Horm IGF Res; 2013 Dec; 23(6):229-36. PubMed ID: 23999134
    [Abstract] [Full Text] [Related]

  • 4. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
    Hellgren G, Glad CA, Jonsson B, Johannsson G, Albertsson-Wikland K.
    Growth Horm IGF Res; 2015 Jun; 25(3):127-35. PubMed ID: 25742716
    [Abstract] [Full Text] [Related]

  • 5. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
    Toyoshima MT, Castroneves LA, Costalonga EF, Mendonca BB, Arnhold IJ, Jorge AA.
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
    Carrascosa A, Audí L, Esteban C, Fernández-Cancio M, Andaluz P, Gussinyé M, Clemente M, Yeste D, Albisu MA.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
    [Abstract] [Full Text] [Related]

  • 7. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
    Tauber M, Ester W, Auriol F, Molinas C, Fauvel J, Caliebe J, Nugent T, Fryklund L, Ranke MB, Savage MO, Clark AJ, Johnston LB, Hokken-Koelega AC, NESTEGG group.
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
    [Abstract] [Full Text] [Related]

  • 8. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
    Carrascosa A, Audí L, Fernández-Cancio M, Esteban C, Andaluz P, Vilaró E, Clemente M, Yeste D, Albisu MA, Gussinyé M.
    J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
    [Abstract] [Full Text] [Related]

  • 9. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G, Baur F, Schweizer R, Ranke MB.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [Abstract] [Full Text] [Related]

  • 10. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
    Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ.
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
    [Abstract] [Full Text] [Related]

  • 11. The impact of the d3-growth hormone receptor (d3-GHR) polymorphism on the therapeutic effect of growth hormone replacement in children with idiopathic growth hormone deficiency in Poland.
    Szmit-Domagalska J, Petriczko E, Drozdzynska M, Adler G, Horodnicka-Jozwa A, Ciechanowicz A, Walczak M.
    Neuro Endocrinol Lett; 2016 Sep; 37(4):282-288. PubMed ID: 27857044
    [Abstract] [Full Text] [Related]

  • 12. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
    Baş F, Darendeliler F, Aycan Z, Çetinkaya E, Berberoğlu M, Sıklar Z, Öcal G, Timirci Ö, Çetinkaya S, Darcan Ş, Gökşen Şimşek D, Bideci A, Cinaz P, Böber E, Demir K, Bereket A, Turan S, Atabek ME, Tütüncüler F, Isbir T, Bozkurt N, Kabataş Eryılmaz S, Uzunhan O, Küçükemre Aydın B, Bundak R.
    Horm Res Paediatr; 2012 Sep; 77(2):85-93. PubMed ID: 22456308
    [Abstract] [Full Text] [Related]

  • 13. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
    Dörr HG, Bettendorf M, Hauffa BP, Mehls O, Rohrer T, Stahnke N, Pfäffle R, Ranke MB, German KIGS Group.
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
    [Abstract] [Full Text] [Related]

  • 14. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
    Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
    [Abstract] [Full Text] [Related]

  • 15. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
    Audí L, Carrascosa A, Esteban C, Fernández-Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L, Spanish SGA Study Group.
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
    [Abstract] [Full Text] [Related]

  • 16. The exon3-deleted growth hormone receptor gene polymorphism (d3-GHR) is associated with insulin and spontaneous growth in short SGA children (NESGAS).
    Wegmann MG, Thankamony A, Roche E, Hoey H, Kirk J, Shaikh G, Ivarsson SA, Söder O, Dunger DB, Juul A, Jensen RB.
    Growth Horm IGF Res; 2017 Aug; 35():45-51. PubMed ID: 28719834
    [Abstract] [Full Text] [Related]

  • 17. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
    Meyer S, Schaefer S, Stolk L, Arp P, Uitterlinden AG, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Weise A, Pfützner A, Kann PH.
    Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
    [Abstract] [Full Text] [Related]

  • 18. Association of the growth hormone receptor gene polymorphisms with mandibular height in a Korean population.
    Kang EH, Yamaguchi T, Tajima A, Nakajima T, Tomoyasu Y, Watanabe M, Yamaguchi M, Park SB, Maki K, Inoue I.
    Arch Oral Biol; 2009 Jun; 54(6):556-62. PubMed ID: 19344888
    [Abstract] [Full Text] [Related]

  • 19. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
    Wan L, Chen WC, Tsai Y, Kao YT, Hsieh YY, Lee CC, Tsai CH, Chen CP, Tsai FJ.
    Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
    [Abstract] [Full Text] [Related]

  • 20. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
    Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL, Johannsson G.
    J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.